|
||
|
| Home |  |
Firm Description | |
Sectors Covered | |
Completed Transactions | |
Testimonials | |
Principals | |
M&A Report and Publications |
|
Contact Us | |
| Acquiring Party | Forest Laboratories, Inc. (NYSE: FRX), a US-based pharmaceutical company. |
|---|---|
| Transferring Party | Cerexa, Inc., a privately-held biopharmaceutical company. |
| Sector | Biopharmaceuticals |
| Date | January 11, 2007 |
| Analysis Forest obtains development and marketing rights worldwide excluding Japan to Ceftaroline, a novel antibiotic in Phase 3 clinical trials, an antibiotic in preclinical development and an option to a third early-stage antibiotic. Deal Value -- $493.6m plus $100m in potential milestone payments. | |
The Walden Group is a leading healthcare investment banking firm specializing in mergers, acquisitions and strategic transactions. It also invests its own funds and, together with its expert operational partners, provides value-added services to help special companies reach critical milestones. This information is copyright © 2004-2007 The Walden Group, Inc. This information is provided as a service to the public but remains the intellectual property of The Walden Group, Inc and may not be reproduced in any manner without the written permission of The Walden Group, Inc. The information contained in the transactions table was derived from publicly available and other sources. Transaction analysis and other information are based, in part, upon public comments, Walden Group research and judgments, and reporting and research of others. The information is not intended to be relied upon as pronouncements by the transaction participants or for any other reason. | |